title: [Adjuvant chemotherapy of soft tissue sarcoma].
abstract: The rôle of chemotherapy in the treatment of operable soft tissue sarcomas is still debatable. In high-grade tumors, randomized trials using adjuvant chemotherapy have resulted in controversial results. A recent meta-analysis showed a higher median disease-free survival in groups with chemotherapy compared to controls. Doxorubicin, ifosfamide and dacarbazine are the majors drugs. Their combination in adjuvant treatment is currently being investigated. Neoadjuvant chemotherapy has allowed conservative surgery in initially unoperable tumors, but its role in primarily operable tumors remains to be defined.
authors.affiliation: Service de cancérologie, CHU Henri-Mondor, Créteil, France.
authors.forename: E
authors.initials: E
authors.lastname: Lévy
authors.forename: P
authors.initials: P
authors.lastname: Thirion
authors.forename: P
authors.initials: P
authors.lastname: Piedbois
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D009367:Neoplasm Staging; D011379:Prognosis; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis
chemical_list: D003606:Dacarbazine; D004317:Doxorubicin; D007069:Ifosfamide
vernacular_title: Chimiothérapie adjuvante des sarcomes des tissus mous.